February 10, 2020
1 min read

VERNACULAR: Venous stent patency remains high at 2 years

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Rates of patency and freedom from target lesion revascularization in patients receiving a venous stent were high at 2 years, according to new data from the VERNACULAR trial.

As Healio previously reported, at 1 year, the self-expanding nitinol venous stent (Venovo, BD) exceeded performance goals in patients with iliac vein or femoral vein occlusive disease. Jose I. Almeida, MD, FSVS, FACS, RPVI, RVT, founder of Miami Vein Center and voluntary professor of surgery in the division of vascular and endovascular surgery at the University of Miami Miller School of Medicine, presented 2-year results at the International Symposium on Endovascular Therapy.

In the cohort of 170 patients who had symptomatic venous outflow obstruction of at least 50% in the iliac and femoral veins (mean age, 52 years; 37% men), 86.4% were available for follow-up at 2 years.

Among those patients, 84.3% maintained primary patency at 2 years, and 89.4% were free from TLR and target vessel revascularization, Almeida said.

In patients with post-thrombotic syndrome, 75.4% maintained patency and 82.8% were free from TLR and TVR, while in patients with nonthrombotic iliac veins, 95.4% maintained patency and 97.3% were free from TLR and TVR, he said.

There were no stent fractures in any patient at 2 years, according to the researchers.

“Follow-up is ongoing through 3 years,” Almeida said during the presentation.

The FDA approved the venous stent in March 2019, as Healio previously reported. – by Erik Swain


Almeida JI, et al. Venous Interventions: Chronic and Acute Venous Occlusions. Presented at: the International Symposium on Endovascular Therapy (ISET); Jan. 22-25, 2020; Hollywood, Fla.

Disclosures: The study was funded by BD. Almeida reports he served on the data safety monitoring board for the trial without compensation.